NEW YORK, Feb. 18, 2014 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Chindex International, Inc. ("Chindex" or the "Company") (NasdaqGS: CHDX) (ISIN: US1694671074) (CUSIP: 169467107) concerning the proposed acquisition of Chindex by a buyer consortium of an affiliate of TPG, an affiliate of Shanghai Fosun Pharmaceutical Group Co., Ltd., and Ms. Roberta Lipson, the CEO of the Company, in a transaction having an implied equity value of approximately $369 million.
The investigation concerns whether the Chindex directors are breaching their fiduciary duties by failing to adequately shop the Company and maximize shareholder value. Under the terms of the agreement, shares of Chindex will be converted into the right to receive $19.50 in cash only for each share of Chindex common stock. However, the Price to EBITDA, Revenue, Total Assets, and Book Value multiples are below the averages of comparable transactions.
Chindex shareholders seeking more information about this acquisition are advised to contact Robert Willoughby at firstname.lastname@example.org or 212-661-1100 or 888-476-6529, ext. 237.
Pomerantz LLP, with offices in New York, Chicago, Florida, and San Diego, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz LLP pioneered the field of securities class actions. Today, more than 75 years later, the Pomerantz LLP continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of defrauded investors. See www.pomerantzlaw.com.
212-661-1100 ext. 237
SOURCE Pomerantz LLP